Dr. Bin Yang 杨彬
Chief Physician
Department of Medical Oncology, Hubei Cancer Hospital, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of malignant tumors, including lung cancer, esophageal cancer, and mediastinal tumors.
Dr. Yang is a Chief Physician with a medical doctorate. Professional roles include positions with the China Anti-Cancer Association, Hubei Immunology Society, Hubei Anti-Cancer Association, and Hubei Clinical Oncology Society.
Professional roles
- Member, Tumor Supportive Care Committee, China Anti-Cancer Association
- Youth Member, Clinical Chemotherapy Committee, China Anti-Cancer Association
- Vice Chair, Tumor Precision Therapy Committee, Hubei Immunology Society
- Council Member, Hubei Clinical Oncology Society
Name order: in Chinese the family name comes first (Yang Bin). Papers usually list the name as Bin Yang or Yang B.
Selected publications
33 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mol Genet Genomics, 2025 (senior author): Proto-oncogene DEK binds to pre-mRNAs and regulates the alternative splicing of Hippo signaling genes in HeLa cells. PubMed 40075046
- Cancer Biomark, 2025 (first author): Stepwise single-cell data identifies RNA binding proteins associated with the development of head and neck cancer and tumor microenvironment remodeling. PubMed 40171814
- Int J Biol Sci, 2025 (senior author): Advancement Opportunities and Endeavor of Innovative Targeted Therapies for Small Cell Lung Cancer. PubMed 39897044
- World J Clin Cases, 2022 (senior author): Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature. PubMed 35949835
- Case Rep Oncol, 2021 (senior author): A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient. PubMed 33976649
- Can Respir J, 2020 (first author): Effects of Apatinib on the "Stemness" of Non-Small-Cell Lung Cancer Cells In Vivo and Its Related Mechanisms. PubMed 32849930
- Case Rep Oncol, 2020 (senior author): Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report. PubMed 32595469
- Mol Genet Genomic Med, 2020 (first author): LncRNA DLX6-AS1 increases the expression of HIF-1α and promotes the malignant phenotypes of nasopharyngeal carcinoma cells via targeting MiR-199a-5p. PubMed 31782911
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion